Cebranopadol Shows Low Abuse Potential in Clinical Trial
Tris Pharma announced positive clinical data from its intranasal human abuse potential (HAP) study of cebranopadol. The study demonstrated...
Cebranopadol Shows Low Abuse Potential in Clinical Trial
Tris Pharma announced positive results from a Phase 1 intranasal human abuse potential (HAP) study of cebranopadol. The study...
Tevogen Bio Secures $10M Grant Funding
Tevogen Bio (Nasdaq: TVGN), a clinical-stage immunotherapy biotech company, has secured up to $10 million in non-dilutive grant funding...
Silexion Shows Strong Tumor Reduction in Pancreatic Cancer Models
Silexion Therapeutics announced positive preclinical data for SIL-204, its RNAi therapeutic candidate targeting KRAS-driven cancers. The data validates systemic...
March Biosciences Gets FDA Orphan Drug for Lymphoma
March Biosciences received FDA orphan drug designation for MB-105, its CD5-targeted CAR-T cell therapy for relapsed/refractory CD5-positive T-cell lymphoma....
SAB Bio Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
SAB Bio announced positive topline data from a Phase 1 trial of SAB-142, a human anti-thymocyte immunoglobulin being developed...
Positive Topline Results in 5-MeO-DMT Study for Alcohol Use Disorder
Atai Life Sciences announced positive topline results from a Phase 2a study of BPL-003, a synthetic intranasal 5-MeO-DMT formulation,...
Oncomatryx Secures €25M to Advance OMTX705 Clinical Trials
Oncomatryx, a biopharmaceutical company developing antibody-drug conjugates (ADCs), secured €25 million to advance clinical trials of OMTX705, a first-in-class...
Lerodalcibep Shows Promise in HoFH Phase 3 Study
LIB Therapeutics‘ Phase 3 LIBerate-HoFH study results for lerodalcibep, a novel PCSK9 inhibitor, in patients with homozygous familial hypercholesterolemia...
Pediatric Erydex Safety in Ataxia-Telangiectasia: Long-Term Study Results
Quince Therapeutics announced the publication of long-term safety data from Ataxia-Telangiectasia (A-T) patients treated with EryDex for at least...